MHMohamed Salah Eldeen Hussein

Mohamed Salah Eldeen Hussein

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mohamed Salah Eldeen Hussein has a total of 48 co-authors. Here are the top co-authors by number of shared publications:

  • Arulkumaran Shanmugam

    Georgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA 30912

    3 shared publications
  • Daniel Swafford

    Georgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA 30912

    3 shared publications
  • Muthusamy Thangaraju

    ¶Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, Augusta, GA 30912

    3 shared publications
  • Pandelakis A. Koni

    §Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129; and

    3 shared publications
  • Punithavathi Ranganathan

    Georgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA 30912

    3 shared publications
  • Puttur D. Prasad

    Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University , Augusta, GA

    3 shared publications

Latest Publications

  • Open Access

    Fast receptor-antigen dissociation kinetics promote CAR-T cell tumor infiltration, functional fitness, and antitumor efficacy in solid tumors

    by Rui Mao, Huidong Shi, Mohamed S. Hussein, Bela Karia, Obed Koomson, Ramses Sadek, Vamsi Kota, Nicholas R.J. Gascoigne, Yukai He

    Background: CAR-T cells have shown limited efficacy against solid tumors, where they face two major challenges: restricted tumor infiltration and sustained intensive engagement that drive them to exhaustion. Conventional CAR design has largely emphasized high-affinity interactions with slow dissociation, further limiting tumor infiltration and exacerbating exhaustion and dysfunction. We hypothesize that most current CARs are kinetically over-stabilized for solid tumors and that a fast-on/fast-off, “ cheek-kiss ” mode of engagement permits transient CAR–antigen disengagement, thereby facilitating tumor infiltration and preserving CAR-T cell fitness in tumor mass. Methods: We identified two monoclonal antibodies targeting the same epitope of epidermal growth factor receptor with comparable k on but distinct k off rates: cetuximab (Cet) and its humanized derivative H1. CAR-T cells incorporating these binders were evaluated in vitro and in vivo . Large, established human tumor xenografts were treated with low-dose CAR-T cells in NSG mice to model conditions of limited T cell availability and sustained tumor antigen exposure. Results: Cet and H1 exhibited comparable k on but markedly different k off rates, with H1 displaying fast-off kinetics with approximately 18-fold shorter binding dwell time. As CARs, H1 showed reduced antigen occupancy and less stable tumor-T cell engagement than Cet. Despite comparable in vitro cytotoxicity, H1 CAR-T cells accumulated more efficiently following tumor stimulation. At high doses, both CAR-T cell products eradicated established tumors. Under low-dose conditions, however, H1 CAR-T cells exhibited superior expansion, persistence, tumor infiltration, and antitumor efficacy, whereas Cet CAR-T cells showed limited expansion and only transient tumor control. Cet CAR-T cells progressively downregulated surface CAR expression, increased PD-1 expression, and exhibited reduced tumor infiltration and impaired functional recovery. In contrast, H1 CAR-T cells preserved surface CAR expression, exhibited greater tumor infiltration, maintained a less exhausted, more central memory-like phenotype, and retained effector function. Conclusion: Fast-on/fast-off binding kinetics enhance CAR-T tumor infiltration, expansion, persistence, and functional fitness, resulting in improved control of established solid tumors. The data provides a rationale for shifting CAR design from affinity optimization toward kinetic optimization to improve the efficacy and safety of CAR-T therapy for solid tumors. WHAT IS ALREADY KNOWN ON THIS TOPIC: CAR design has largely focused on antigen-binding affinity, whereas the contribution of binding kinetics, particularly the dissociation rate, to CAR-T cell function, expansion, persistence, tumor infiltration, and antitumor efficacy remains poorly defined. WHAT THIS STUDY ADDS: In this study, we found that, compared with slow-off binding, fast-off kinetics enhance CAR-T cell tumor infiltration, expansion, persistence, and functional fitness in tumor-bearing mice, revealing previously underappreciated effects of antigen-binding kinetics on CAR-T cell tumor infiltration and performance in solid tumors. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY: This study provides a rationale for incorporating antigen-binding kinetics into CAR design and optimization. The TCR-inspired fast-on/fast-off antigen engagement may help CAR T cells maintain fitness during sustained antigen exposure and thereby improve their infiltration, persistence, and antitumor activity in solid tumors.

  • Open Access

    The role of levosimendan as inotropic agents in patients with LV dysfunction admitted to ICU post cardiac surgery

    by Mohamed Salah Eldeen Hussein, Ahmed Abdel Rahman Batah, Nael Samir Selit, Mohamed Fawzy Ablelaleem

    BACKGROUND: Coronary artery bypass graft (CABG) surgery is the standard of care for the management of patients with three-vessel and left main coronary artery disease (CAD) with viable myocardium. Positive inotropic agents are the treatment of choice in patients with LV dysfunction post CABG. Levosimendan is an inotropic drug that has three major mechanisms of action: positive inotropy, vasodilation, and cardiac cytoprotection. Levosimendan is a calcium sensitizer, it improves myocardial contractility by sensitising troponin C to calcium without increasing myocardial oxygen consumption and without impairing relaxation and diastolic function. AIM: The aim of this study was to determine the effect of levosimendan compared to the conventional inotropic agents on the outcomes of patients with LV dysfunction undergoing CABG. METHODS: It is a prospective observational study that patients were divided into 2 groups of 50 patients each. Group A received intravenous levosimendan (at a dose of 0.2μg per kilogram of body weight per minute for 1 hour, followed by a dose of 0.1μg per kilogram per minute for 23 hours), with the infusion started at the induction of anesthesia while Group B which included patients who received conventional drugs. Clinical examination, Hemodynamic data and Laboratory investigations pre-operative and post-operative were collected.

  • Chimeric antigen receptor engineered T cells and their application in the immunotherapy of solid tumours

    by Rui Mao, Mohamed S. Hussein, Yukai He

    In this article, we reviewed the current literature studies and our understanding of the parameters that affect the chimeric antigen receptor T cells (CAR-T's) activation, effector function,in vivopersistence, and antitumour effects. These factors include T cell subsets and their differentiation stages, the components of chimeric antigen receptors (CAR) design, the expression promoters and delivery vectors, and the CAR-T production process. The CAR signalling and CAR-T activation were also studied in comparison to TCR. The last section of the review gave special consideration of CAR design for solid tumours, focusing on strategies to improve CAR-T tumour infiltration and survival in the hostile tumour microenvironment. With several hundred clinical trials undergoing worldwide, the pace of CAR-T immunotherapy moves from bench to bedside is unprecedented. We hope that the article will provide readers a clear and comprehensive view of this rapidly evolving field and will help scientists and physician to design effective CAR-Ts immunotherapy for solid tumours.


  • Novel low‐avidity glypican‐3 specific CARTs resist exhaustion and mediate durable antitumor effects against HCC

    by Leidy D. Caraballo Galva, Xiaotao Jiang, Mohamed S. Hussein, Huajun Zhang, Rui Mao, Pierce Brody, Yibing Peng, Aiwu Ruth He, Mercy Kehinde‐Ige, Ramses Sadek, et al.

    Background and Aims: Chimeric antigen receptor engineered T cells (CARTs) for HCC and other solid tumors are not as effective as they are for blood cancers. CARTs may lose function inside tumors due to persistent antigen engagement. The aims of this study are to develop low‐affinity monoclonal antibodies (mAbs) and low‐avidity CARTs for HCC and to test the hypothesis that low‐avidity CARTs can resist exhaustion and maintain functions in solid tumors, generating durable antitumor effects. Methods and Results: New human glypican‐3 (hGPC3) mAbs were developed from immunized mice. We obtained three hGPC3‐specific mAbs that stained HCC tumors, but not the adjacent normal liver tissues. One of them, 8F8, bound an epitope close to that of GC33, the frequently used high‐affinity mAb, but with approximately 17‐fold lower affinity. We then compared the 8F8 CARTs to GC33 CARTs for their in vitro function and in vivo antitumor effects. In vitro, low‐avidity 8F8 CARTs killed both hGPC3high and hGPC3low HCC tumor cells to the same extent as high‐avidity GC33 CARTs. 8F8 CARTs expanded and persisted to a greater extent than GC33 CARTs, resulting in durable responses against HCC xenografts. Importantly, compared with GC33 CARTs, there were 5‐fold more of 8F8‐BBz CARTs in the tumor mass for a longer period of time. Remarkably, the tumor‐infiltrating 8F8 CARTs were less exhausted and apoptotic, and more functional than GC33 CARTs. Conclusion: The low‐avidity 8F8‐BBz CART resists exhaustion and apoptosis inside tumor lesions, demonstrating a greater therapeutic potential than high‐avidity CARTs.


  • Open Access

    The Wnt–β-Catenin–IL-10 Signaling Axis in Intestinal APCs Protects Mice from Colitis-Associated Colon Cancer in Response to Gut Microbiota

    by Daniel Swafford, Arulkumaran Shanmugam, Punithavathi Ranganathan, Indumathi Manoharan, Mohamed S. Hussein, Nikhil Patel, Humberto Sifuentes, Pandelakis A. Koni, Puttur D. Prasad, Muthusamy Thangaraju, et al.

    Loss of immune tolerance to gut microflora is inextricably linked to chronic intestinal inflammation and colitis-associated colorectal cancer (CAC). The LRP5/6 signaling cascade in APCs contributes to immune homeostasis in the gut, but whether this pathway in APCs protects against CAC is not known. In the current study, using a mouse model of CAC, we show that the LRP5/6–β-catenin–IL-10 signaling axis in intestinal CD11c+ APCs protects mice from CAC by regulating the expression of tumor-promoting inflammatory factors in response to commensal flora. Genetic deletion of LRP5/6 in CD11c+ APCs in mice (LRP5/6ΔCD11c) resulted in enhanced susceptibility to CAC. This is due to a microbiota-dependent increased expression of proinflammatory factors and decreased expression of the immunosuppressive cytokine IL-10. This condition could be improved in LRP5/6ΔCD11c mice by depleting the gut flora, indicating the importance of LRP5/6 in mediating immune tolerance to the gut flora. Moreover, mechanistic studies show that LRP5/6 suppresses the expression of tumor-promoting inflammatory factors in CD11c+ APCs via the β-catenin–IL-10 axis. Accordingly, conditional activation of β-catenin specifically in CD11c+ APCs or in vivo administration of IL-10 protected LRP5/6ΔCD11c mice from CAC by suppressing the expression of inflammatory factors. In summary, in this study, we identify a key role for the LRP5/6–β-catenin–IL-10 signaling pathway in intestinal APCs in resolving chronic intestinal inflammation and protecting against CAC in response to the commensal flora.


  • Open Access

    Canonical Wnt Signaling in CD11c+ APCs Regulates Microbiota-Induced Inflammation and Immune Cell Homeostasis in the Colon

    by Daniel Swafford, Arulkumaran Shanmugam, Punithavathi Ranganathan, Mohamed S. Hussein, Pandelakis A Koni, Puttur D. Prasad, Muthusamy Thangaraju, Santhakumar Manicassamy

    Aberrant Wnt/β-catenin signaling occurs in several inflammatory diseases, including inflammatory bowel disease and inflammatory bowel disease–associated colon carcinogenesis. However, its role in shaping mucosal immune responses to commensals in the gut remains unknown. In this study, we investigated the importance of canonical Wnt signaling in CD11c+ APCs in controlling intestinal inflammation. Using a mouse model of ulcerative colitis, we demonstrated that canonical Wnt signaling in intestinal CD11c+ APCs controls intestinal inflammation by imparting an anti-inflammatory phenotype. Genetic deletion of Wnt coreceptors, low-density lipoprotein receptor–related proteins 5 and 6 (LRP5/6) in CD11c+ APCs in LRP5/6ΔCD11c mice, resulted in enhanced intestinal inflammation with increased histopathological severity of colonic tissue. This was due to microbiota-dependent increased production of proinflammatory cytokines and decreased expression of immune-regulatory factors such as IL-10, retinoic acid, and IDO. Mechanistically, loss of LRP5/6-mediated signaling in CD11c+ APCs resulted in altered microflora and T cell homeostasis. Furthermore, our study demonstrates that conditional activation of β-catenin in CD11c+ APCs in LRP5/6ΔCD11c mice resulted in reduced intestinal inflammation with decreased histopathological severity of colonic tissue. These results reveal a mechanism by which intestinal APCs control intestinal inflammation and immune homeostasis via the canonical Wnt-signaling pathway.


  • GPR81, a Cell-Surface Receptor for Lactate, Regulates Intestinal Homeostasis and Protects Mice from Experimental Colitis

    by Punithavathi Ranganathan, Arulkumaran Shanmugam, Daniel Swafford, Amol Suryawanshi, Pushpak Bhattacharjee, Mohamed S. Hussein, Pandelakis A Koni, Puttur D. Prasad, Zoya B. Kurago, Muthusamy Thangaraju, et al.

    At mucosal sites such as the intestine, the immune system launches robust immunity against invading pathogens while maintaining a state of tolerance to commensal flora and ingested food Ags. The molecular mechanisms underlying this phenomenon remain poorly understood. In this study, we report that signaling by GPR81, a receptor for lactate, in colonic dendritic cells and macrophages plays an important role in suppressing colonic inflammation and restoring colonic homeostasis. Genetic deletion of GPR81 in mice led to increased Th1/Th17 cell differentiation and reduced regulatory T cell differentiation, resulting in enhanced susceptibility to colonic inflammation. This was due to increased production of proinflammatory cytokines (IL-6, IL-1β, and TNF-α) and decreased expression of immune regulatory factors (IL-10, retinoic acid, and IDO) by intestinal APCs lacking GPR81. Consistent with these findings, pharmacological activation of GPR81 decreased inflammatory cytokine expression and ameliorated colonic inflammation. Taken together, these findings identify a new and important role for the GPR81 signaling pathway in regulating immune tolerance and colonic inflammation. Thus, manipulation of the GPR81 pathway could provide novel opportunities for enhancing regulatory responses and treating colonic inflammation.


  • Synthesis and Characterization of Novel BMI1 Inhibitors Targeting Cellular Self-Renewal in Hepatocellular Carcinoma

    by Monica Bartucci, Mohamed S. Hussein, Eric Huselid, Kathleen Flaherty, Michele Patrizii, Saurabh V. Laddha, Cindy Kui, Rachel A. Bigos, John A. Gilleran, Mervat M. S. El Ansary, et al.

    Background Hepatocellular carcinoma (HCC) represents one of the most lethal cancers worldwide due to therapy resistance and disease recurrence. Tumor relapse following treatment could be driven by the persistence of liver cancer stem-like cells (CSCs). The protein BMI1 is a member of the polycomb epigenetic factors governing cellular self-renewal, proliferation, and stemness maintenance. BMI1 expression also correlates with poor patient survival in various cancer types. Objective We aimed to elucidate the extent to which BMI1 can be used as a potential therapeutic target for CSC eradication in HCC. Methods We have recently participated in characterizing the first known pharmacological small molecule inhibitor of BMI1. Here, we synthesized a panel of novel BMI1 inhibitors and examined their ability to alter cellular growth and eliminate cancer progenitor/stem-like cells in HCC with different p53 backgrounds. Results Among various molecules examined, RU-A1 particularly downregulated BMI1 expression, impaired cell viability, reduced cell migration, and sensitized HCC cells to 5-fluorouracil (5-FU) in vitro. Notably, long-term analysis of HCC survival showed that, unlike chemotherapy, RU-A1 effectively reduced CSC content, even as monotherapy. BMI1 inhibition with RU-A1 diminished the number of stem-like cells in vitro more efficiently than the model compound C-209, as demonstrated by clonogenic assays and impairment of CSC marker expression. Furthermore, xenograft assays in zebrafish showed that RU-A1 abrogated tumor growth in vivo. Conclusions This study demonstrates the ability to identify agents with the propensity for targeting CSCs in HCC that could be explored as novel treatments in the clinical setting.